Tag : COAST-V trial

CONFERENCE UPDATE

Impact of ixekizumab on structural lesions in SIJ of patients with r-axSpA: Post-hoc analysis of the COAST-V trial
Ixekizumab (IXE) is a monoclonal antibody that selectively inhibits interleukin (IL)-17A, which plays a pivotal role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Previously, IXE has been demonstrated to improve signs and symptoms of r-axSpA, but the effect of IXE on structural lesions in the sacroiliac joints (SIJ) of r-axSpA patients remains unknown.